614 related articles for article (PubMed ID: 25211298)
1. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract][Full Text] [Related]
2. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
[TBL] [Abstract][Full Text] [Related]
4. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Kast RE; Ramiro S; Lladó S; Toro S; Coveñas R; Muñoz M
J Neurooncol; 2016 Feb; 126(3):425-31. PubMed ID: 26603162
[TBL] [Abstract][Full Text] [Related]
5. Drug Repositioning in Oncology.
Serafin MB; Bottega A; da Rosa TF; Machado CS; Foletto VS; Coelho SS; da Mota AD; Hörner R
Am J Ther; 2021 Jan-Feb 01; 28(1):e111-e117. PubMed ID: 31033488
[TBL] [Abstract][Full Text] [Related]
6. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
7. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Kesari S; Schiff D; Henson JW; Muzikansky A; Gigas DC; Doherty L; Batchelor TT; Longtine JA; Ligon KL; Weaver S; Laforme A; Ramakrishna N; Black PM; Drappatz J; Ciampa A; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2008 Jun; 10(3):300-8. PubMed ID: 18403492
[TBL] [Abstract][Full Text] [Related]
9. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch ME; Kast RE; Karpel-Massler G; Mayer B; Zolk O; Schmitz B; Scheuerle A; Maier L; Bullinger L; Mayer-Steinacker R; Schmidt C; Zeiler K; Elshaer Z; Panther P; Schmelzle B; Hallmen A; Dwucet A; Siegelin MD; Westhoff MA; Beckers K; Bouche G; Heiland T
Neurooncol Adv; 2021; 3(1):vdab075. PubMed ID: 34377985
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
11. The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
Kast RE
Chin J Cancer; 2015 Apr; 34(4):161-5. PubMed ID: 25963312
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
Kast RE; Halatsch ME
Arch Med Res; 2012 Apr; 43(3):243-7. PubMed ID: 22564423
[TBL] [Abstract][Full Text] [Related]
13. Artesunate in glioblastoma therapy: Case reports and review of clinical studies.
Strik H; Efferth T; Kaina B
Phytomedicine; 2024 Jan; 123():155274. PubMed ID: 38142662
[TBL] [Abstract][Full Text] [Related]
14. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Kang SG; Kim JS; Park K; Kim JS; Groves MD; Nam DH
Oncol Rep; 2006 Jan; 15(1):7-13. PubMed ID: 16328028
[TBL] [Abstract][Full Text] [Related]
15. Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
Seiz M; Nölte I; Pechlivanis I; Freyschlag CF; Schmieder K; Vajkoczy P; Tuettenberg J
Neurosurg Rev; 2010 Jul; 33(3):375-81; discussion 381. PubMed ID: 20306105
[TBL] [Abstract][Full Text] [Related]
16. Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation.
Kast RE
Ann Pharm Fr; 2021 Sep; 79(5):481-488. PubMed ID: 33689795
[TBL] [Abstract][Full Text] [Related]
17. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Kilickap S; Oztoprak I; Yucel B
Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
[No Abstract] [Full Text] [Related]
18. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
20. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Gilbert MR; Gonzalez J; Hunter K; Hess K; Giglio P; Chang E; Puduvalli V; Groves MD; Colman H; Conrad C; Levin V; Woo S; Mahajan A; de Groot J; Yung WK
Neuro Oncol; 2010 Nov; 12(11):1167-72. PubMed ID: 20729242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]